Technology Programs

Three platforms. One engineering mission.

Each PrismVeno program addresses a distinct, unsolved problem in envenomation medicine — designed from first principles with precision engineering, not incremental biology.

Research Program

VenoSense / VenoChip

Rapid venom identification at the point of care.

VenoSense is a microfluidic lateral-flow cartridge platform designed to identify venom type — snake, spider, scorpion, or marine — at the point of care. The VenoChip is the disposable cartridge component: a precision-engineered microfluidic device that processes a small blood or wound-fluid sample and delivers a readable result within minutes.

The problem

Clinicians treating envenomation often cannot identify the offending species, forcing empirical antivenom administration — which carries significant risk of adverse reaction, waste of scarce antivenom supply, and suboptimal patient outcomes.

Our approach

PrismVeno's engineering approach focuses on microfluidic channel geometry, surface chemistry integration, and lateral-flow signal optimization to achieve reliable species-level or venom-class identification from minimal sample volumes in field-compatible form factors.

Platform highlights

  • Microfluidic lateral-flow cartridge architecture
  • Point-of-care form factor — no lab infrastructure required
  • Multi-species venom class detection concept
  • Designed for field, clinical, and EMS deployment

VenoSense / VenoChip is a research program. No device is FDA cleared, clinically validated, or commercially available.

Development Concept

VenoFlow

Precision antivenom workflow engineering.

VenoFlow is a precision fluid-handling system concept designed to support antivenom reconstitution, dosing calculation, and administration workflows. The platform addresses the mechanical and human-factors challenges of antivenom delivery — particularly in resource-limited, high-stress clinical environments.

The problem

Antivenom administration is error-prone: reconstitution is complex, dosing is weight- and species-dependent, and administration rates must be carefully managed to minimize adverse reactions. These are engineering problems as much as clinical ones.

Our approach

VenoFlow applies precision fluid-handling engineering — including controlled-rate delivery mechanisms, guided reconstitution workflows, and human-factors-optimized interface design — to reduce error and improve consistency in antivenom administration.

Platform highlights

  • Controlled-rate antivenom delivery mechanism concept
  • Guided reconstitution workflow design
  • Human-factors-optimized interface
  • Field and clinical environment compatibility

VenoFlow is a development concept. No device is FDA cleared, clinically validated, or commercially available.

Research Program

VenoLab / VenoChip Research

Human-relevant envenomation research platforms.

VenoLab is PrismVeno's microphysiological research platform — a family of organ-on-chip devices that model envenomation pathophysiology in human-relevant tissue constructs. The VenoChip Research variant is a configurable microfluidic chip designed to support venom toxicology, antivenom efficacy screening, and mechanistic research without reliance on animal models.

The problem

Animal models for envenomation research are expensive, ethically constrained, and often poor predictors of human response. Existing in vitro models lack the physiological complexity needed to generate clinically translatable data.

Our approach

PrismVeno applies organ-on-chip microfluidic engineering to create tissue-perfused models of envenomation target organs — enabling researchers to study venom effects and antivenom efficacy in human-cell-based systems with controlled, reproducible fluidic conditions.

Platform highlights

  • Organ-on-chip microfluidic architecture
  • Human-cell-based tissue constructs
  • Configurable for multiple venom/tissue combinations
  • Designed for academic and pharmaceutical research partners

VenoLab / VenoChip Research is a research program. No device is FDA cleared, clinically validated, or commercially available.

Interested in collaborating on platform development?

PrismVeno is actively seeking research partners, clinical advisors, and technology vendors to advance each platform.